Trial · NCT00748969
Clinical Trial of Growth Hormone in MPS I, II, and VI
NCT00748969, Phase 2, Phase 3, Terminated, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; results first posted 2014-11-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial of Growth Hormone in MPS I, II, and VI. Trials, record NCT00748969. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00748969
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial of Growth Hormone in MPS I, II, and VI
- NCT number
- NCT00748969
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 2 participants, actual
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
- Interventions
- Somatropin (DNA origin)
- First posted
- 2008-09-09
- Last updated
- 2018-09-05
- Results first posted
- 2014-11-24
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Growth Velocity From Baseline to End of Study Year 1. | 12 months | |
| Secondary | Safety: Number Drug Related SAEs | 1 months |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Growth Velocity From Baseline to End of Study Year 1. | 12 months | Zero participants analyzed in the No growth hormone treatment group due to subject withdrew from study as soon as informed they were assigned the no treatment group. | cm/yr | NUMBER |
| SECONDARY | Safety: Number Drug Related SAEs | 1 months | Study stopped early due to inability to enroll participants. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Growth Velocity From Baseline to End of Study Year 1. | Growth Hormone Treatment | NA | cm/yr | ||
| Safety: Number Drug Related SAEs | Growth Hormone Treatment | 0 | Participants | ||
| Safety: Number Drug Related SAEs | No Growth Hormone Treatment | 0 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Growth Hormone Treatmen | 1 | |
| Overall Study | STARTED | No Growth Hormone Treatment in Year 1 | 1 | |
| Overall Study | COMPLETED | Growth Hormone Treatmen | 0 | |
| Overall Study | COMPLETED | No Growth Hormone Treatment in Year 1 | 0 | |
| Overall Study | NOT COMPLETED | Growth Hormone Treatmen | 1 | |
| Overall Study | NOT COMPLETED | No Growth Hormone Treatment in Year 1 | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | GH Treatment | 1 | 1 | 1 |
| other | Headache | Nervous system disorders | No GH Treatment | 0 | 0 | 0 |
| other | worsening OSA | Respiratory, thoracic and mediastinal disorders | GH Treatment | 1 | 1 | 1 |
| other | worsening OSA | Respiratory, thoracic and mediastinal disorders | No GH Treatment | 0 | 0 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | GH Treatment | ||
| Total, all-cause mortality | No GH Treatment | ||
| Total, other adverse events | GH Treatment | 1 | 1 |
| Total, other adverse events | No GH Treatment | 0 | 0 |
| Total, serious adverse events | GH Treatment | 0 | 1 |
| Total, serious adverse events | No GH Treatment | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00748969
GET https://conductscience.org/api/trials/v1/NCT00748969/registered